🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

EyePoint, Inc. EYPT R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://eyepoint.bio
Company Profile ↓
$4.58
-58.40% 1Y
Mkt Cap$394.85M
P/E-1.22
P/B35.08
52W High$18.85
52W Low$4.48
Book Value$0.40
EPS (TTM)$-3.75

Company Overview

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Recent Developments

  • Dec 2025 Revenue of $31.37M (-27.5% YoY); net profit $-231.96M.
  • Trailing 12 Months Year-on-year growth — revenue +161.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR -8.8%, profit CAGR -42.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-8.83%
1 Year:161.70%

Compounded Profit Growth

5 Years:-42.28%
1 Year:-

Stock Price Performance

1 Year:-58.40%
6 Months:-70.92%
3 Months:-61.12%
1 Month:-64.30%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 1% of range
$4.48 $18.85
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)29.80 · Oversold
Price Performance
1M-64.30%
3M-61.12%
6M-70.92%
1Y-58.40%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -8.8% CAGR over 5 years.
  • Earnings shrank at -42.3% CAGR over 5 years.
  • Trading 75.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.22
Industry PE
25.17
Forward P/E
-1.49
PEG Ratio
-
Book Value
$0.40
Price to Book
35.08
P/S
429.51
EV/EBITDA
-4.11
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-8.83%
Profit 5Y
-42.28%
Revenue (YoY)
161.70%
Earnings (YoY)
-

Profitability & Returns

ROCE
-70.85%
ROE
-148.70%
ROA
-74.85%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-1.09
EPS (TTM)
$-3.75

Balance Sheet & Liquidity

Debt/Equity
0.47
Quick Ratio
4.30
Current Ratio
4.50
Debt
$17.62M
Total Assets
$228.19M
Current Assets
$328.65M
Working Capital
$291.63M

Ownership

Promoter Holding
3.52%
Chg in Prom Hold
-0.07%
FII / Inst Holding
111.34%
Chg in FII Hold
0.13%

Financial Snapshot

Enterprise Value
$394.85M
Total Revenue (TTM)
$2.79M
EBITDA
$-314.43M
Free Cash Flow
$-243.39M
Operating Cash Flow
$-240.11M
Shares Outstanding
86.21M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 EYPT EyePoint, Inc. R2KR3KPHARMA 4.58 -1.22 $394.85M 0.00% -70.85% -148.70% -8.83% -42.28%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----277.00K5.97M590.00K701.00K385.00K933.00K928.00K715.00K486.00K2.44M2.01M7.21M2.51M8.63M7.49M4.12M15.70M7.32M9.01M9.06M9.29M11.56M10.01M7.68M9.11M15.20M11.68M9.48M10.52M-24.45M5.33M966.00K620.00K696.00K507.00K
Cost of Revenue ----------------------------------805.00K165.00K721.00K375.00K528.00K-
Gross Profit ----------------------------------23.65M5.17M245.00K245.00K168.00K-
Operating Expenses ----------------------------------72.48M67.39M62.27M70.59M87.39M-
Operating Income -4.98M-5.24M-5.10M-6.46M-7.19M-94.00K-5.16M-6.14M-6.01M-5.81M-4.68M-9.78M-13.55M-11.01M-14.65M-10.16M-14.06M-8.98M-11.44M-11.15M-1.96M-10.94M-10.98M-15.31M-18.28M-19.22M-18.40M-21.55M-22.76M-14.40M-33.32M-34.55M-32.75M--48.84M-62.23M-62.02M-70.34M-87.23M-97.38M
EBITDA -----------------------------------48.34M-61.69M-61.45M-57.86M-86.59M-
Interest Expense ---------------------------------14.00K------
Pretax Income -----------------------------------45.20M-59.33M-59.73M-67.42M-84.88M-
Tax Provision ----------------------------------093.00K0186.00K-50.00K-
Net Income -4.93M-5.19M-5.04M-6.39M-7.16M-67.00K-5.14M-6.12M-5.98M-5.78M-6.98M-34.43M-33.13M-11.59M-19.24M-11.50M-15.65M-10.41M-13.17M-12.95M-3.80M-12.28M-10.01M-16.70M-20.98M-19.41M-18.42M-21.16M-22.92M-12.61M-29.28M-30.83M-29.36M--45.20M-59.43M-59.73M-67.61M-84.83M-94.47M
Diluted EPS -0.17-0.18-0.15--------------------0.35-0.58-0.56-0.52-0.49-0.56-0.61-0.33-0.55-0.58-0.54--0.65-0.85-0.85-0.81-0.99-1.09
R&D Expense 3.48M3.72M3.07M-4.18M3.17M3.32M-3.82M4.27M3.33M4.76M6.23M-3.80M3.96M3.48M-4.85M3.28M4.09M5.48M5.61M8.50M9.95M12.99M11.16M13.62M15.73M17.36M30.14M29.82M29.54M-58.57M55.50M47.75M-72.15M83.61M

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 23.05M4.96M3.53M2.14M3.47M26.57M1.62M7.54M2.96M4.57M20.36M34.44M-41.40M46.02M43.27M31.37M
Cost of Revenue -------------8.33M4.63M3.71M2.07M
Gross Profit -------------33.08M41.39M39.56M29.30M
Operating Expenses -------------112.02M116.45M185.41M272.74M
Operating Income 9.09M-10.00M-25.21M-12.03M-13.49M6.42M-21.77M-18.58M-26.27M-39.02M-47.86M-37.29M--78.94M-75.07M-145.85M-243.43M
EBITDA --------------96.62M-69.00M-129.23M-229.34M
Interest Expense -------------3.19M1.25M14.00K33.00K
Pretax Income --------------102.25M-70.71M-130.78M-231.68M
Tax Provision -------------083.00K90.00K279.00K
Net Income 8.75M-8.63M-24.84M-11.90M-13.36M6.35M-21.55M-18.48M-53.17M-86.12M-56.79M-45.39M--102.25M-70.80M-130.87M-231.96M
Diluted EPS 0.46-0.44-1.19-0.52-0.490.21-0.68-0.52------2.74-1.82-2.32-3.17
R&D Expense 6.99M6.86M7.04M7.00M9.57M12.09M14.38M14.88M16.18M18.50M15.37M17.42M28.50M49.64M64.66M132.93M221.04M

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --47.11M20.60M16.25M22.67M32.37M31.62M18.68M71.67M78.17M72.97M91.72M-180.36M355.18M418.46M364.00M
Current Assets --------------172.81M344.80M383.31M328.65M
Cash & Equivalents 6.90M15.51M12.91M4.62M6.90M15.33M19.12M15.31M16.90M38.78M45.26M22.21M44.91M-95.63M281.26M99.70M101.82M
Inventory --------------2.89M3.91M2.31M1.81M
Receivables --------------15.50M805.00K607.00K651.00K
Total Liabilities --9.68M6.96M8.55M7.75M9.00M10.74M5.34M59.98M40.53M64.64M73.18M-83.99M88.86M81.96M57.88M
Current Liabilities --5.03M3.18M3.30M2.13M3.35M5.09M5.29M21.66M21.46M11.52M14.89M-34.54M63.26M49.05M37.02M
Long Term Debt --------017.31M17.62M47.22M37.98M36.56M29.31M---
Total Debt --------------45.77M4.91M21.86M20.77M
Total Equity 23.54M33.04M37.43M13.64M7.70M14.92M23.37M20.88M13.34M11.69M37.63M8.33M18.54M-96.37M266.32M336.50M306.11M
Shares Outstanding --------------34.08M49.04M68.27M82.83M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 9.90M-3.17M-9.00M-8.74M---16.32M-20.49M-21.91M-56.70M-14.44M-50.10M-65.00M1.88M-126.23M-240.11M
Investing Cash Flow -2.07M-9.50M606.00K6.36M---4.46M13.58M-16.89M-213.00K-362.00K-33.12M-17.27M-3.31M-219.35M68.58M
Financing Cash Flow 802.00K10.06M114.00K4.67M--16.99M8.50M60.67M33.86M37.49M216.90M-690.00K187.07M164.02M173.65M
Capital Expenditure -15.00K-133.00K-405.00K-68.00K-248.00K-161.00K-113.00K-147.00K-108.00K-213.00K-362.00K-156.00K-2.15M-3.48M-4.05M-3.28M
Free Cash Flow 9.88M-3.30M-9.41M-8.81M---16.43M-20.64M-22.02M-56.91M-14.80M-50.25M-67.16M-1.61M-130.28M-243.39M

Ratios (Annual)

Figures in %.

Metric Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------79.9%89.9%91.4%93.4%
Operating Margin % 39.4%-201.5%-715.0%-561.4%-388.4%24.2%-1,344.1%-246.4%-887.3%-853.6%-235.0%-108.3%--190.7%-163.1%-337.1%-776.0%
Net Margin % 38.0%-173.8%-704.3%-555.3%-384.5%23.9%-1,330.1%-245.2%-1,795.7%-1,884.2%-278.9%-131.8%--247.0%-153.8%-302.4%-739.4%
ROE % 26.5%-23.0%-182.1%-154.5%-89.5%27.2%-103.2%-138.6%-455.0%-228.9%-681.8%-244.8%--106.1%-26.6%-38.9%-75.8%
ROCE % --23.8%-144.7%-92.9%-65.7%22.1%-82.1%-138.8%-52.5%-68.8%-77.9%-48.5%--54.1%-25.7%-39.5%-74.5%

Shareholding Pattern

Insiders
3.52%
Institutions
111.34%
Public Float
115.40%

Top Institutional Holders

#Holder% HeldSharesValue
1 Montanova Capital LLC 9.62% 8.30M $37.17M
2 Blackrock Inc. 8.66% 7.46M $33.44M
3 Cormorant Asset Management, LP 8.12% 7.00M $31.36M
4 Federated Hermes, Inc. 6.59% 5.68M $25.45M
5 Adage Capital Partners GP L.L.C. 5.60% 4.83M $21.63M
6 Franklin Resources, Inc. 5.58% 4.81M $21.54M
7 Commodore Capital Lp 5.34% 4.60M $20.61M
8 Jupiter Topco LLC 4.37% 3.77M $16.89M
9 Vanguard Capital Management LLC 4.21% 3.63M $16.26M
10 Paradigm Biocapital Advisors LP 3.35% 2.89M $12.95M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EYPT

Google News Fri, 04 Sep 2026

EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPVHhhR1BRaUVmcldVTmNQLTNvdUhmTkVnYXhiNUFZS2JoZFRGakEzVldvSW50djE4TWU0UHlST1Bwb3ZIYVlpazZqN1FBRUtESG0waDVESnlPcGVMVUpDTmdVWDJJMGh4TWtnYXlpeGlGT0c1ckZ1SGlCa2NKU1VMd1Iyd3ZWMjlUM055cW…

Google News Wed, 02 Sep 2026

Four retinal-disease studies are slated for Los Angeles. EyePoint will present them. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQVlRnNmo4OEdGaVdLdXRseFNkbTN3ZmlNdi1Ic3Fkc05nUm1abERDODNaRXotekt3Y0tOTk4xc1dnZGNnSkFQcnhUMmQ2cHRqdlVob0Y2TjNqcDdCOXZQN0FqcVYxNWNjaHp6aTZUMVAyNDBwajBZSlk4TU5zZXItdkl2TVE2ajRiUEVVSk…

Google News Wed, 02 Sep 2026

EyePoint stock drops as TD Cowen downgrades (EYPT:NASDAQ) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOdUxIMVJRZ0cta3lCZzFTUFZ0bVRGMTNldWY2WFNuWU9JQWdrMDgyN01HeE9od0hIQkNCRVRUOUJ5RWlhYkpHMEtFQ3pCR2hjYmFOM2dGdndUb25La2pnZnZGZnRsYUs2ajdrWjBKd3Y2eXVPX2k1MlRabVhBcmQtWFcweEs?oc=5" targ…

Google News Sun, 06 Sep 2026

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP - Morningstar

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxQZmlISC1mS3RoWTZzWWxMRk51RTZfT1lRdFNiVHRNWk5jWXBkbjdINFUtRWFtWmtBa1NST0x0WC1xNXV2TU1RV3YzazdhZVN3M2x6LTFwUWRxS0hsMENFaWkyT0hQMWhFNU1YMm9vNGZjWmRlMXg2YktXWndxTXVkQnhVTS05eW1IN1JrM3…

Google News hu, 20 Aug 2026

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PR Newswire

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxOWklMYlBIQ3NVTGNrb0tMem9xNy1xclZIcmE4TnM3MWl0ZzJ2b0QwSG1pVnpsNkxfQ1VfbU5VdlIyQmI2Z0JfNE9qTEpidS1MWFpGZHlGM1pLc0J2MWlkREpBbzRGSEpTMUo5bFJUSFNfcjk0LUtvYUVTMUNXTmNWVWpVdlZJMjY4QUtOcD…

Google News Mon, 17 Aug 2026

The Surprising Reason EyePoint Just Crashed 67%, Sacrificing A Breakout - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPanNZVWtvQnJDbFpLbGw4R25TZ3AwVDhiVnFvTEg3NDFjbi0zOFo0MkhkaXRCa2I2WkxIay03Zk5wSjFFTzBWT3FFUzBkWlFNeWtTeHJFTjhJUWc4ek5aMjF1bWVBcWpoaXMxeUVGUnR1aVItTFlXcmVUR3B5NW5MV0hPNk92dUJyYnVqcE…

EYPT — Frequently Asked Questions

What is the current share price of EyePoint, Inc. (EYPT)?

As of 2026-09-07 16:24 PDT, EyePoint, Inc. (EYPT) trades at $4.58 on NasdaqGM. Its 52-week range is $4.48 to $18.85.

What is the market capitalisation of EYPT?

EyePoint, Inc. (EYPT) has a market capitalisation of $394.85M on NasdaqGM.

What is the P/E ratio of EYPT?

EYPT trades at a trailing price-to-earnings (P/E) ratio of -1.22. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 35.08.

What is the return on equity (ROE) of EYPT?

EYPT has a return on equity (ROE) of -148.70%. Its return on capital employed (ROCE) is -70.85%.

Is EYPT a good stock to buy?

This page provides a data-driven analysis of EyePoint, Inc. (EYPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space